Dr. Debra N. Yeboa
Claim this profileM D Anderson Cancer Center
Area of expertise
Brain Tumor
Debra N. Yeboa has run 4 trials for Brain Tumor. Some of their research focus areas include:
Brain Metastasis
Debra N. Yeboa has run 2 trials for Brain Metastasis. Some of their research focus areas include:
Affiliated Hospitals
M D Anderson Cancer Center
Clinical Trials Debra N. Yeboa is currently running
Chemotherapy + Radiation
for Brain Cancer
This phase II trial studies how well temozolomide and radiation therapy work in treating patients with IDH wildtype historically lower grade gliomas or non-histological molecular glioblastomas. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The goal of this clinical research study is to compare receiving new radiation therapy doses and volumes to the prior standard treatment for patients with historically grade II or grade III IDH wild-type gliomas, which may now be referred to as IDH wildtype molecular glioblastomas at some institutions. Receiving temozolomide in combination with radiation therapy may also help to control the disease.
Recruiting
1 award
Phase 2
12 criteria
Radiation Therapy vs Observation
for Meningioma
This trial studies if radiation therapy helps prevent the return of grade II meningioma after surgery. Radiation therapy uses powerful x-rays to destroy any leftover cancer cells. The goal is to see if this improves patient outcomes compared to just monitoring them. Radiation therapy has shown success in stabilizing tumor growth and reducing recurrence risk.
Recruiting
2 awards
Phase 3
12 criteria
More about Debra N. Yeboa
Clinical Trial Related
5 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Debra N. Yeboa has experience with
- Radiation Therapy
- Stereotactic Radiosurgery
- Temozolomide
- MR-LINAC
- Spine Radiosurgery
- Clinical Observation
Breakdown of trials Debra N. Yeboa has run
Brain Tumor
Brain Metastasis
Oligodendroglioma
Anaplastic astrocytoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Debra N. Yeboa specialize in?
Debra N. Yeboa focuses on Brain Tumor and Brain Metastasis. In particular, much of their work with Brain Tumor has involved Stage IV patients, or patients who are IDH negative.
Is Debra N. Yeboa currently recruiting for clinical trials?
Yes, Debra N. Yeboa is currently recruiting for 4 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Debra N. Yeboa has studied deeply?
Yes, Debra N. Yeboa has studied treatments such as Radiation Therapy, Stereotactic Radiosurgery, Temozolomide.
What is the best way to schedule an appointment with Debra N. Yeboa?
Apply for one of the trials that Debra N. Yeboa is conducting.
What is the office address of Debra N. Yeboa?
The office of Debra N. Yeboa is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.